Wayfair surges on double (JP Morgan) upgrade – 'tides have turned positive'
BARRON’S reports: Wayfair W +24.42% shares soared Monday after landing a double upgrade from a J.P. Morgan JPM +0.50% analyst arguing that “tides ...
STAT reports:
HEAVY hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects. The company’s stock valuation also surged, hitting $29 billion, an astonishing feat for a company that currently sells zero products.
But was there good reason for so much enthusiasm? Several vaccine experts asked by STAT concluded that, based on the information made available by the Cambridge, Mass.-based company, there’s really no way to know how impressive — or not — the vaccine may be.
While Moderna blitzed the media, it revealed very little information — and most of what it did disclose were words, not data. That’s important: If you ask scientists to read a journal article, they will scour data tables, not corporate statements. With science, numbers speak much louder than words.
To read the full story, please click here.
You may also want to read this: “Dow ends 390 points lower after report cast doubt on Moderna’s coronavirus vaccine candidate“.
'I'm scared', says Boeing whistleblower, after two others suffer mysterious deaths
DSV could face $16m bill after helicopter is written off in haulage accident
FAK rate hikes holding, with strong demand into peak season predicted
Déjà vu as major ocean carriers scramble for tonnage and containers
Indian trade disrupted as port congestion forces liner services to skip calls
Ecommerce boom may be opening the doors for smugglers
Don't get too confident for Q2, market risks haven't disappeared, warns Yang Ming chief
Comment on this article